文献速递肝病消化道肿瘤与早癌

手术时间对BCLC 0-A期肝细胞癌肝切除患者结局的影响

Impact of time to surgery in the outcome of patients with liver resection for BCLC 0-A stage hepatocellular carcinoma.
PubMed 文献 · J Hepatol · 2017-10-06

研究纳入2006至2016年因BCLC 0-A期单个肝细胞癌行肝切除的100例患者,评估从诊断到手术的时间(TTS)对复发与生存的影响。TTS≥3个月组与<3个月组相比,术后并发症更高(36% vs 16%,p=0.02),但肿瘤复发率、无复发生存、复发后可移植性及五年意向治疗总生存均无显著差异。结论认为TTS≥3个月不损害肿瘤学结局。

要点

  • BCLC 0-A期单个肝细胞癌患者TTS≥3个月与<3个月相比,肿瘤复发率无显著差异(32% vs 32%,p=1.00)。
  • TTS≥3个月组术后并发症发生率高于<3个月组(36% vs 16%,p=0.02)。
  • TTS≥3个月组与<3个月组五年意向治疗总生存无显著差异(82% vs 80%,p=0.20)。

核心结论

  • BCLC 0-A期单个肝细胞癌患者手术时间≥3个月不损害肿瘤学结局。
  • 在安全范围内延长手术时间可允许术前充分评估及伦理性地测试新辅助治疗,以减少根治性切除后仍较高的肿瘤复发率。

研究设计与样本

  • 研究纳入2006至2016年因BCLC 0-A期单个肝细胞癌行肝切除的全部患者,共100例。
  • 评估手术时间对复发率、无复发生存、复发后可移植性及意向治疗总生存的影响,并采用倾向性评分匹配确保可比性。

主要发现

  • 手术在诊断后0.6至77个月进行,中位手术时间为3个月,四分位距1.8-4.6个月。
  • 无术后死亡。
  • 与手术时间<3个月组相比,手术时间≥3个月组(其中70%患者手术时间为3-6个月)术后并发症发生率更高(36% vs 16%,p=0.02)。
  • 手术时间≥3个月组与<3个月组肿瘤复发率相似(32% vs 32%,p=1.00),无复发生存相似(37% vs 48%,p=0.42)。
  • 手术时间≥3个月组与<3个月组复发后可移植性相似(63% vs 50%,p=0.48),五年意向治疗总生存相似(82% vs 80%,p=0.20)。

临床怎么用

  • 作者认为,BCLC 0-A期单个肝细胞癌患者手术时间≥3个月可不损害肿瘤学结局。
  • 作者认为,在安全范围内延长手术时间可允许术前充分评估及伦理性地测试新辅助治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The Barcelona Clinic Liver Cancer (BCLC) guidelines recommend resection for very early and early single hepatocellular carcinoma (HCC) patients. It is not known whether a delay in resection from the time of diagnosis (the time to surgery [TTS], i.e. the elapsed time from diagnosis to surgery) affects outcomes. We aim to evaluate the impact of TTS on recurrence and survival outcomes in patients with HCC. METHODS: All patients resected for BCLC stage 0-A single HCC from 2006 to 2016 were studied to evaluate the impact of TTS on recurrence rate, recurrence-free survival (RFS), transplantability following recurrence, and intention-to-treat overall survival (ITT-OS). Propensity score matching (PSM) was further performed to ensure comparability. RESULTS: The study population included 100 patients. Surgery was performed between 0.6 and 77 months after diagnosis (median TTS: three months; interquartile range: 1.8-4.6 months). There was no post-operative mortality. Compared to those with TTS <3 months, patients with TTS ≥3 months (70% of these patients had TTS 3-6 months) had a higher post-operative morbidity (36% vs. 16%, p = 0.02), a similar tumor recurrence rate (32% vs. 32%, p = 1.00), RFS (37% vs. 48%, p = 0.42), transplantability following tumor recurrence (63% vs. 50%, p = 0.48), and five-year ITT-OS (82% vs. 80%, p = 0.20). Similar results were observed after PSM. CONCLUSION: Patients with BCLC stage 0-A single HCC can undergo surgery with TTS ≥3 months without impaired oncologic outcomes. An increase in the TTS within a safe range could allow time for proper evaluation before surgery, and ethical testing of new neoadjuvant treatments, aiming to reduce the high rate of tumor recurrence despite curative resection. LAY SUMMARY: A delay of ≥3 months in time to resection after diagnosis in HCC patients meeting the European Association for the Study of Liver Disease/American Association for the Study of Liver Disease criteria for resection does not affect oncological and long-term outcomes compared to those with a delay to surgery of <3 months.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Lim C, Bhangui P, Salloum C, et al. Impact of time to surgery in the outcome of patients with liver resection for BCLC 0-A stage hepatocellular carcinoma. J Hepatol. 2017. PMID: 28989094. doi:10.1016/j.jhep.2017.09.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。